Shares of Jazz Pharmaceuticals (JAZZ) have gained 10.8% over the past four weeks to close the last trading session at $111.60, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$174.83 indicates a potential upside of 56.7%.The average comprises 18 short-term price targets ranging from a low of $113 to a high of$230, with a standard deviation of $33.43. While the lowest estimate i ...